journal article·2025-11

Disassembly of Prion Protein Fragment 106‐126 Aggregates Driven by an Organopalladium‐Modified Polyoxometalate

Yanfei Lv, Chenxi Zhang, Yuxia Fu, Zhaohui Wu, Bole Li, Xiaotong Xu, Yunfei Guo, Lei He, Yu‐Fei Song

Small· Volume 21· Issue 46
Publisher page

Abstract

Abstract Prion disorders are characterized by the pathological misfolding of cellular prion proteins into the infectious and aggregated isoforms (PrP Sc ). Due to the dynamic folding‐unfolding equilibrium of prion protein, therapeutic strategies targeting PrP Sc often suffer from reversible binding and incomplete efficacy. Herein, an organopalladium‐modified polyoxometalate (Pd‐MnMo 6 ) is synthesized by covalently grafting [Pd(tpy)Cl] onto Mn‐Anderson (denoted as MnMo 6 ). The Pd‐MnMo 6 effectively disassembles 92.8% of preformed PrP106‐126 fibrils and exhibits significant cytoprotection effect in SH‐SY5Y cells. This protection effect is evidenced by the attenuation of PrP106‐126 aggregates‐induced cytotoxicity, suppression of excessive reactive oxygen species production, and mitigation of mitochondrial membrane depolarization. Mechanism studies reveal that Pd‐MnMo 6 interacts with PrP106‐126 through multiple interaction modes: electrostatic interaction, hydrogen bonding, π – π stacking and metal coordination. Analysis of the dynamic binding between Pd‐MnMo 6 and a PrP106‐126 decamer reveals that electrostatic attraction drives the initial approach of Pd‐MnMo 6 to the PrP106‐126 N‐terminus, enabling subsequent π – π stacking (between the tpy ligand and histidine residues) and Pd coordination to methionine sites. This synergistic interaction network disrupts the dynamic folding equilibrium of PrP106‐126, leading to irreversible binding and effective disassembly of PrP106‐126 aggregates.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Prion Diseases and Protein Misfolding · Alzheimer's disease research and treatments · Polyoxometalates: Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Chemical Resource Engineering Beijing University of Chemical Technology Beijing 100029 China

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China

Funding

Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities

References (61)

Show source-provided references
1. 10.1038/s41573-023-00823-110.1038/s41573-023-00823-1 ↗
2. 10.1021/acs.chemrev.1c0094110.1021/acs.chemrev.1c00941 ↗
3. 10.1039/D3CS01065A10.1039/D3CS01065A ↗
4. 10.1021/acs.chemrev.1c0019610.1021/acs.chemrev.1c00196 ↗
5. 10.1038/s41572-024-00497-y10.1038/s41572-024-00497-y ↗
6. 10.1038/s41467-024-46360-210.1038/s41467-024-46360-2 ↗
7. 10.1021/jacs.4c1059010.1021/jacs.4c10590 ↗
8. 10.1038/s41594-020-0441-510.1038/s41594-020-0441-5 ↗
9. 10.1038/380345a010.1038/380345a0 ↗
10. 10.1021/acschemneuro.3c0041710.1021/acschemneuro.3c00417 ↗
11. 10.1021/acsami.3c0496910.1021/acsami.3c04969 ↗
12. 10.1002/adma.20230839310.1002/adma.202308393 ↗
13. 10.1039/C5MT00133A10.1039/C5MT00133A ↗
14. 10.1016/j.biochi.2023.03.01210.1016/j.biochi.2023.03.012 ↗
15. 10.3390/ph1204015410.3390/ph12040154 ↗
16. 10.1016/j.jinorgbio.2019.11072110.1016/j.jinorgbio.2019.110721 ↗
17. 10.3390/ijms2206301510.3390/ijms22063015 ↗
18. 10.1002/anie.20240560510.1002/anie.202405605 ↗
19. 10.1002/adma.20241872310.1002/adma.202418723 ↗
20. 10.26599/POM.2022.914001110.26599/POM.2022.9140011 ↗
21. 10.1002/smll.20220731510.1002/smll.202207315 ↗
22. 10.1002/smll.20230553910.1002/smll.202305539 ↗
23. 10.1002/anie.20230381710.1002/anie.202303817 ↗
24. 10.1002/smll.20231200910.1002/smll.202312009 ↗
25. 10.1002/anie.20201731810.1002/anie.202017318 ↗
26. 10.1021/cb500623910.1021/cb5006239 ↗
27. 10.1002/chem.20240352010.1002/chem.202403520 ↗
28. 10.1039/C4CS00097H10.1039/C4CS00097H ↗
29. 10.1093/nsr/nwae22610.1093/nsr/nwae226 ↗
30. 10.1021/jacs.8b1253710.1021/jacs.8b12537 ↗
31. 10.1002/anie.20211533610.1002/anie.202115336 ↗
32. 10.1016/j.ccr.2020.21326010.1016/j.ccr.2020.213260 ↗
33. 10.1002/anie.20191052110.1002/anie.201910521 ↗
34. 10.1021/acsnano.2c1147610.1021/acsnano.2c11476 ↗
35. 10.1021/jacs.0c0839510.1021/jacs.0c08395 ↗
36. 10.1002/prot.34007030210.1002/prot.340070302 ↗
37. 10.1002/bip.2085310.1002/bip.20853 ↗
38. 10.1002/smll.20241006310.1002/smll.202410063 ↗
39. 10.1038/s41573-024-01105-010.1038/s41573-024-01105-0 ↗
40. 10.1016/j.ccr.2023.21561610.1016/j.ccr.2023.215616 ↗
41. 10.1038/s41467-024-44737-x10.1038/s41467-024-44737-x ↗
42. 10.1021/acschemneuro.8b0003310.1021/acschemneuro.8b00033 ↗
43. 10.1002/alz.08728310.1002/alz.087283 ↗
44. 10.1038/s41467-023-40345-310.1038/s41467-023-40345-3 ↗
45. 10.1021/acsnano.3c1112510.1021/acsnano.3c11125 ↗
46. 10.1021/acs.jpcb.4c0604810.1021/acs.jpcb.4c06048 ↗
47. 10.1016/0003-2697(87)90157-610.1016/0003-2697(87)90157-6 ↗
48. 10.1002/adma.20240913010.1002/adma.202409130 ↗
49. 10.1021/ic102331x10.1021/ic102331x ↗
50. 10.1021/ja045958z10.1021/ja045958z ↗
51. 10.1002/anie.20200373210.1002/anie.202003732 ↗
52. 10.1016/j.jcat.2024.11581810.1016/j.jcat.2024.115818 ↗
53. 10.1002/cbic.20070063310.1002/cbic.200700633 ↗
54. 10.1002/anie.20100706710.1002/anie.201007067 ↗
55. 10.1021/ja502789e10.1021/ja502789e ↗
56. 10.1002/jcc.2288510.1002/jcc.22885 ↗
57. 10.1002/jcc.2681210.1002/jcc.26812 ↗
58. 10.1038/s41598-024-69850-110.1038/s41598-024-69850-1 ↗
59. 10.1002/anie.20160515110.1002/anie.201605151 ↗
60. 10.1016/j.str.2020.08.00510.1016/j.str.2020.08.005 ↗
61. 10.1021/jacs.3c0375610.1021/jacs.3c03756 ↗